➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Dow
Baxter
McKesson
Medtronic
AstraZeneca

Last Updated: July 10, 2020

DrugPatentWatch Database Preview

NEOSAR Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Neosar patents expire, and what generic alternatives are available?

Neosar is a drug marketed by Bedford and Teva Parenteral and is included in two NDAs.

The generic ingredient in NEOSAR is cyclophosphamide. There are nineteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the cyclophosphamide profile page.

US ANDA Litigation and Generic Entry Outlook for Neosar

A generic version of NEOSAR was approved as cyclophosphamide by BAXTER HLTHCARE on May 21st, 2008.

  Start Trial

Summary for NEOSAR
Drug patent expirations by year for NEOSAR
Recent Clinical Trials for NEOSAR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
City of Hope Medical CenterEarly Phase 1
Children's Oncology GroupPhase 2
Medical College of WisconsinPhase 2

See all NEOSAR clinical trials

US Patents and Regulatory Information for NEOSAR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bedford NEOSAR cyclophosphamide INJECTABLE;INJECTION 087442-004 Jul 8, 1983 DISCN No No   Start Trial   Start Trial   Start Trial
Teva Parenteral NEOSAR cyclophosphamide INJECTABLE;INJECTION 040015-005 Apr 29, 1993 DISCN No No   Start Trial   Start Trial   Start Trial
Bedford NEOSAR cyclophosphamide INJECTABLE;INJECTION 087442-002 Feb 16, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Teva Parenteral NEOSAR cyclophosphamide INJECTABLE;INJECTION 040015-001 Apr 29, 1993 DISCN No No   Start Trial   Start Trial   Start Trial
Bedford NEOSAR cyclophosphamide INJECTABLE;INJECTION 087442-005 Mar 30, 1989 DISCN No No   Start Trial   Start Trial   Start Trial
Bedford NEOSAR cyclophosphamide INJECTABLE;INJECTION 087442-001 Feb 16, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Teva Parenteral NEOSAR cyclophosphamide INJECTABLE;INJECTION 040015-004 Apr 29, 1993 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Dow
Baxter
McKesson
Medtronic
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.